HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYN
Refractory Angina Gene Therapy Demonstrates Safety and Efficacy in Phase 2 Trial

Nearly half of participants were able to engage in normal physical activity without angina at 6 months post-treatment.

New Data Supports Breyanzi’s Expansion to Chronic Lymphocytic Leukemia

Breyanzi is currently approved for the second-line or later treatment of large B-cell lymphomas.

DMD Cell Therapy Continues to Demonstrate Efficacy After 18-month Follow-up

Patients continued to show statistically significant upper limb performance improvements.

Lifileucel Creeps Closer to Clinic for Melanoma, NSCLC

Iovance is on track to complete its rolling BLA submission for lifileucel in the post-anti-PD1 melanoma indication in the first quarter of 2023.

Around the Helix: Cell and Gene Therapy Company Updates – January 25, 2023

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Logic-gated CAR T Therapy Cleared for Lymphoma Trials

The CD19/CD20 dual-targeted CAR is currently under investigation in an investigator-initiated study in UCLA.